# A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

> **NCT07069335** · PHASE1 · RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib 150 MG

## Key facts

- **NCT ID:** NCT07069335
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07069335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07069335, "A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07069335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*